P622. In a Dutch real-life inflammatory bowel disease score cohort with 90% prior anti-tumour necrosis factor failure, vedolizumab showed a 25% remission rate: a retrospective multicentre study
| Dokumenttyp: | Artikel |
|---|---|
| Erscheinungsdatum: | 2016 |
| Reihe/Periodikum: | Journal of Crohn's and Colitis ; volume 10, issue suppl 1, page S416.1-S416 ; ISSN 1873-9946 1876-4479 |
| Verlag/Hrsg.: |
Oxford University Press (OUP)
|
| Schlagwörter: | Gastroenterology / General Medicine |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-29434459 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1093/ecco-jcc/jjw019.741 |
